Skip to main content

FDA approves Sentra's PMA supplemental

The Food and Drug Administration approved Sientra Inc.'s (Nasdaq: SIEN) PMA supplemental allowing commercialization of its OPUS-branded breast implant products lifting the stock price 93 cents to close at $11.98.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.